New finding could lead to development of hundreds of new antibiotics

EU-funded scientists have discovered a new molecule in Streptomyces bacteria that could be exploited to make the bacteria produce hundreds of novel antibiotics. The work, which is published online by the Proceedings of the National Academy of Sciences (PNAS), was partly supported by the EU-funded ACTINOGEN (Integrating genomics-based applications to exploit actinomycetes as a resource for new antibiotics) project.

When colonies of bacteria such as Streptomyces are under stress and so more vulnerable to attack from other bacteria, a signal is sent out across the colony that stimulates the bacteria to make antibiotics as a defence mechanism.

Drug manufacturers have exploited this characteristic of the Streptomyces bacteria for some time, using certain strains to produce antibiotics on an industrial scale. In most of these cases, the compounds used to trigger the bacterial defence mechanism are relatively unstable.

In this latest piece of research, scientists from the University of Warwick and the John Innes Centre in the UK succeeded in identifying a much more stable group of compounds called 2-alkyl-4-hydroxymethylfuran-3-carboxylic acids (AHFCAs) that could have the potential to stimulate different pathways of antibiotic production in the bacteria. This could eventually lead to the development of many novel antibiotics.

Normally the amounts of these defence-mechanism-triggering compounds produced by the bacteria are too small for chemists to analyse easily. In this study, the scientists used the University of Warwick's 700 MHz NMR (Nuclear Magnetic Resonance) machine to identify the AHFCAs on the basis of just a few micrograms of material.

The chemists combined their newfound knowledge with information on the genetic sequences of some Streptomyces bacteria to show that the AHFCA group of compounds could potentially be used to stimulate the production of both known and new antibiotics. Their hypothesis was confirmed when they added the AHFCAs to colonies of the W81 strain of Streptomyces coelicolor; the bacteria produced methylenomycin antibiotics.

Although methylenomycins are a familiar type of antibiotic, the researchers believe that the AHFCAs could also control the production of novel types of antibiotic.

"Early results also suggest that this approach could switch on novel antibiotic production pathways in up to 50% of Streptomyces bacteria," said Dr Christophe Corre of the University of Warwick, the lead author of the paper. "With thousands of known members of the Streptomyces family that could mean that AHFCAs could unlock hundreds of new antibiotics to replenish our dwindling arsenal of effective antibiotic drugs."

The researchers are now on the lookout for funding to explore the properties of AHFCAs further.

The ACTINOGEN project received approximately EUR 9.4 million in EU funding through the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6).

For more information, please visit:

Proceedings of the National Academy of Sciences (PNAS), http://www.pnas.org

University of Warwick, http://www.warwick.ac.uk

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...